Your Article Summary
See Latest ArticlesRecommendations on the use of 18F-FDG PET in oncology
The Journal of Nuclear Medicine, 03/10/08
Fletcher JW et al. - In a trial to develop recommendations on use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor, it was recommended that 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI
Methods- A search was performed to identify all published randomized controlled trials and systematic reviews in the literature
- An additional search was performed to identify relevant unpublished systematic reviews
- Publications comprised both retrospective and prospective studies of varied methodologic quality
- Anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and impact of 18F-FDG PET on management of cancer pts, were also reviewed
- 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI
- Any positive finding that could lead to a clinically significant change in pt management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results
- 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor
Today in Nuclear Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Spectrum of 18F-FDG PET/CT Appearances in Peritoneal Disease
American Journal of Roentgenology, 12/04/09
The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake
International Journal of Radiation Biology, 12/04/09
Track structure effects in a study of cell killing in normal human skin fibroblasts
International Journal of Radiation Biology, 12/04/09